Avastin VEGF Neutralisation Bioassay

The Avastin (bevacizumab) VEGF Neutralisation bioassay measures activity of the Fab binding affinity against VEGF, reporting the inhibition of VEGF mediated signalling, commensurate to the concentration of Avastin (bevacizumab). BioOutsource are industry experts in the development, optimization and  qualification of bioassays and have applied this expertise to Avastin (bevacizumab) biosimilars to offer the VEGF Neutralisation bioassay to our customers. We have provided services to support clone selection, characterization and similarity activities with assays performed using our existing methodology, adapted to incorporate the customer’s reference standard of choice.

The principle of the Avastin (bevacizumab) VEGF Neutralisation Bioassay is that an engineered cell line is prepared in cell plates. A dilution series of Avastin (bevacizumab) is then prepared and pre-incubated with an optimized concentration of VEGF to allow neutralization to occur before being added to the cell plate. The cell plate is then incubated for a further period of time before the assay is completed and the luminescent signal detected. Sample results are reported as a relative potency measurement against the reference standard material.